Oral Tau Aggregation Inhibitor for Alzheimer’s Disease: Design, Progress and Basis for Selection of the 16 mg/day Dose in a Phase 3, Randomized, Placebo-Controlled Trial of Hydromethylthionine Mesylate

BACKGROUND: Hydromethylthionine mesylate is a tau aggregation inhibitor shown to have exposure-dependent pharmacological activity on cognitive decline and brain atrophy in two completed Phase 3 trials in mild/moderate Alzheimer’s disease (AD). OBJECTIVES: The present report summarises the basis for...

Descripción completa

Detalles Bibliográficos
Autores principales: Wischik, Claude M., Bentham, P., Gauthier, S., Miller, S., Kook, K., Schelter, B. O.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer International Publishing 2022
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9226274/
https://www.ncbi.nlm.nih.gov/pubmed/36281683
http://dx.doi.org/10.14283/jpad.2022.63

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9226274/
https://www.ncbi.nlm.nih.gov/pubmed/36281683
http://dx.doi.org/10.14283/jpad.2022.63

Ejemplares similares